BetterLife Pharma Inc. News Releases

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in...

BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco

Tue, 06 Jan 2026 08:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Francisco, California,...

BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital

Thu, 11 Dec 2025 08:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for development of BETR-001...